{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T19:42:43Z","timestamp":1774640563492,"version":"3.50.1"},"reference-count":31,"publisher":"e-Century Publishing Corporation","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Am J Transl Res"],"DOI":"10.62347\/kbmz4400","type":"journal-article","created":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T04:12:41Z","timestamp":1745899961000},"page":"2790-2799","source":"Crossref","is-referenced-by-count":1,"title":["Immunotherapy combined with targeted therapy and transcatheter arterial chemoembolization: a promising approach for advanced liver cancer"],"prefix":"10.62347","volume":"17","author":[{"given":"Yuanren","family":"Gao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"48694","published-online":{"date-parts":[[2025]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1186\/s12967-020-02225-y","article-title":"Long noncoding RNA lncARSR promotes nonalcoholic fatty liver disease and hepatocellular carcinoma by promoting YAP1 and activating the IRS2\/AKT pathway","volume":"18","author":"Chi","year":"2020","unstructured":"Chi Y, Gong Z, Xin H, Wang Z and Liu Z. Long noncoding RNA lncARSR promotes nonalcoholic fatty liver disease and hepatocellular carcinoma by promoting YAP1 and activating the IRS2\/AKT pathway. J Transl Med 2020; 18: 126.","journal-title":"J Transl Med"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"Chandra V. Immunomodulating effects of transarterial embolization. Radiol Imaging Cancer 2022; 4: e229012.","DOI":"10.1148\/rycan.229012"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s11523-020-00787-x","article-title":"The evolving landscape of checkpoint inhibitor combination therapy in the treatment of advanced hepatocellular carcinoma","volume":"16","author":"Liu","year":"2021","unstructured":"Liu L, Qin S and Zhang Y. The evolving landscape of checkpoint inhibitor combination therapy in the treatment of advanced hepatocellular carcinoma. Target Oncol 2021; 16: 153-163.","journal-title":"Target Oncol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"4880","DOI":"10.1002\/cam4.4818","article-title":"Splenomegaly in predicting the survival of patients with advanced primary liver cancer treated with immune checkpoint inhibitors","volume":"11","author":"Xiao","year":"2022","unstructured":"Xiao LS, Hu CY, Cui H, Li RN, Hong C, Li QM, Huang CY, Dong ZY, Zhu HB and Liu L. Splenomegaly in predicting the survival of patients with advanced primary liver cancer treated with immune checkpoint inhibitors. Cancer Med 2022; 11: 4880-4888.","journal-title":"Cancer Med"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"2960","DOI":"10.1200\/JCO.20.00808","article-title":"Phase Ib study of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma","volume":"38","author":"Finn","year":"2020","unstructured":"Finn RS, Ikeda M, Zhu AX, Sung MW, Baron AD, Kudo M, Okusaka T, Kobayashi M, Kumada H, Kaneko S, Pracht M, Mamontov K, Meyer T, Kubota T, Dutcus CE, Saito K, Siegel AB, Dubrovsky L, Mody K and Llovet JM. Phase Ib study of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma. J Clin Oncol 2020; 38: 2960-2970.","journal-title":"J Clin Oncol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jncc.2022.02.002","article-title":"Cancer incidence and mortality in China, 2016","volume":"2","author":"Zheng","year":"2022","unstructured":"Zheng R, Zhang S, Zeng H, Wang S, Sun K, Chen R, Li L, Wei W and He J. Cancer incidence and mortality in China, 2016. J Natl Cancer Cent 2022; 2: 1-9.","journal-title":"J Natl Cancer Cent"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"148","DOI":"10.5582\/bst.2021.01173","article-title":"The multidisciplinary management of hepatocellular carcinoma with portal vein tumor thrombus","volume":"15","author":"Qiu","year":"2021","unstructured":"Qiu G, Xie K, Jin Z, Jiang C, Liu H, Wan H and Huang J. The multidisciplinary management of hepatocellular carcinoma with portal vein tumor thrombus. Biosci Trends 2021; 15: 148-154.","journal-title":"Biosci Trends"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1080\/00365521.2022.2057198","article-title":"Effi cacy and safety of preoperative transarterial chemoembolization for hepatocellular carcinoma: a systematic review and meta-analysis","volume":"57","author":"Mi","year":"2022","unstructured":"Mi S, Nie Y and Xie C. Effi cacy and safety of preoperative transarterial chemoembolization for hepatocellular carcinoma: a systematic review and meta-analysis. Scand J Gastroenterol 2022; 57: 1070-1079.","journal-title":"Scand J Gastroenterol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"7734","DOI":"10.1002\/cam4.5529","article-title":"Preoperative transcatheter arterial chemoembolization and prognosis of patients with solitary large hepatocellular carcinomas (≥5 cm): multicenter retrospective study","volume":"12","author":"Mo","year":"2023","unstructured":"Mo A, Zhang Q, Xia F, Huang Z, Peng S, Cao W, Mei H, Ren L, Su Y, Gao H and Chen W. Preoperative transcatheter arterial chemoembolization and prognosis of patients with solitary large hepatocellular carcinomas (≥5 cm): multicenter retrospective study. Cancer Med 2023; 12: 7734-7747.","journal-title":"Cancer Med"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.jvir.2021.12.023","article-title":"Authors’ reply to “Re: hepatic artery infusion chemotherapy using fluorouracil, leucovorin, and oxaliplatin versus transarterial chemoembolization as initial treatment for locally advanced hepatocellular carcinoma: a propensity score-matching analysis”","volume":"33","author":"Li","year":"2022","unstructured":"Li S and Zhao M. Authors’ reply to “Re: hepatic artery infusion chemotherapy using fluorouracil, leucovorin, and oxaliplatin versus transarterial chemoembolization as initial treatment for locally advanced hepatocellular carcinoma: a propensity score-matching analysis”. J Vasc Interv Radiol 2022; 33: 461.","journal-title":"J Vasc Interv Radiol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"618206","DOI":"10.3389\/fonc.2021.618206","article-title":"Hepatic arterial infusion chemotherapy combined with PD-1 inhibitors plus lenvatinib versus PD-1 inhibitors plus lenvatinib for advanced hepatocellular carcinoma","volume":"11","author":"Mei","year":"2021","unstructured":"Mei J, Tang YH, Wei W, Shi M, Zheng L, Li SH and Guo RP. Hepatic arterial infusion chemotherapy combined with PD-1 inhibitors plus lenvatinib versus PD-1 inhibitors plus lenvatinib for advanced hepatocellular carcinoma. Front Oncol 2021; 11: 618206.","journal-title":"Front Oncol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1158\/2159-8290.CD-21-1022","article-title":"IFNα potentiates anti-PD-1 efficacy by remodeling glucose metabolism in the hepatocellular carcinoma microenvironment","volume":"12","author":"Hu","year":"2022","unstructured":"Hu B, Yu M, Ma X, Sun J, Liu C, Wang C, Wu S, Fu P, Yang Z, He Y, Zhu Y, Huang C, Yang X, Shi Y, Qiu S, Sun H, Zhu AX, Zhou J, Xu Y, Zhu D and Fan J. IFNα potentiates anti-PD-1 efficacy by remodeling glucose metabolism in the hepatocellular carcinoma microenvironment. Cancer Discov 2022; 12: 1718-1741.","journal-title":"Cancer Discov"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/s41417-020-0186-7","article-title":"Apatinib prevents natural killer cell dysfunction to enhance the efficacy of anti-PD-1 immunotherapy in hepatocellular carcinoma","volume":"28","author":"Yang","year":"2021","unstructured":"Yang Y, Wang C, Sun H, Jiang Z, Zhang Y and Pan Z. Apatinib prevents natural killer cell dysfunction to enhance the efficacy of anti-PD-1 immunotherapy in hepatocellular carcinoma. Cancer Gene Ther 2021; 28: 89-97.","journal-title":"Cancer Gene Ther"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"188391","DOI":"10.1016\/j.bbcan.2020.188391","article-title":"Lenvatinib for hepatocellular carcinoma: from preclinical mechanisms to anti-cancer therapy","volume":"1874","author":"Zhao","year":"2020","unstructured":"Zhao Y, Zhang YN, Wang KT and Chen L. Lenvatinib for hepatocellular carcinoma: from preclinical mechanisms to anti-cancer therapy. Biochim Biophys Acta Rev Cancer 2020; 1874: 188391.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"ref14","unstructured":"Chinese Society of Clinical Oncology Guideline Working Committee. Guidelines for the Diagnosis and Treatment of Primary Hepatocellular Carcinoma (CSCO 2020). Beijing: People’s Medical Publishing House; 2020."},{"key":"ref15","unstructured":"Medical Administration Bureau of the National Health Commission of the People’s Republic of China. Standards for the diagnosis and treatment of primary hepatocellular carcinoma (2017 Edition). Chinese J Pract Surg 2017; 37: 705-720."},{"key":"ref16","unstructured":"Yang XN and Wu YL. Response evaluation criteria in solid tumors-RECIST. Evid Based Med 2004; 4: 85-90, 111."},{"key":"ref17","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.ad.2019.05.009","article-title":"0) to evaluate the severity of side effects of antineoplastic treatments","volume":"112","author":"Freites-Martinez","year":"2020","unstructured":"Freites-Martinez A, Santana N, Arias-Santiago S and Viera A. Using the common terminology criteria for adverse events (CTCAE - Version 5.0) to evaluate the severity of side effects of antineoplastic treatments. Actas Dermo-Sifiliográficas 2020; 112: 90-92.","journal-title":"Actas Dermo-Sifiliogr&#xE1 ficas"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"Sun M, Shang P, Bai J, Li S and Li M. High-intensity focused ultrasound ablation combined with transcatheter arterial chemoembolization improves long-term efficacy and prognosis of primary liver cancer. J Clin Lab Anal 2021; 35: e23633.","DOI":"10.1002\/jcla.23633"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"102022","DOI":"10.1016\/j.clinre.2022.102022","article-title":"TACE alone for hepatocellular carcinoma","volume":"46","author":"Li","year":"2022","unstructured":"Li N, Yang P and Fang J. Transarterial chemoembolization (TACE) plus apatinib vs. TACE alone for hepatocellular carcinoma. Clin Res Hepatol Gastroenterol 2022; 46: 102022.","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"3796","DOI":"10.1002\/cam4.4763","article-title":"Safety and efficacy of atezolizumab plus bevacizumab in elderly patients with hepatocellular carcinoma: a multicenter analysis","volume":"11","author":"Tada","year":"2022","unstructured":"Tada T, Kumada T, Hiraoka A, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, Toyoda H, Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Tanaka T, Ohama H, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Naganuma A, Koizumi Y, Nakamura S, Joko K, Iijima H and Hiasa Y; Real-life Practice Experts for HCC (RELPEC) Study Group and the Hepatocellular Carcinoma Experts from 48 clinics in Japan (HCC 48) Group. Safety and efficacy of atezolizumab plus bevacizumab in elderly patients with hepatocellular carcinoma: a multicenter analysis. Cancer Med 2022; 11: 3796-3808.","journal-title":"Cancer Med"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1002\/hep4.1682","article-title":"Inhibition of CMTM4 sensitizes cholangiocarcinoma and hepatocellular carcinoma to T cell-mediated antitumor immunity through PD-L1","volume":"6","author":"Chui","year":"2022","unstructured":"Chui NN, Cheu JW, Yuen VW, Chiu DK, Goh CC, Lee D, Zhang MS, Ng IO and Wong CC. Inhibition of CMTM4 sensitizes cholangiocarcinoma and hepatocellular carcinoma to T cell-mediated antitumor immunity through PD-L1. Hepatol Commun 2022; 6: 178-193.","journal-title":"Hepatol Commun"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"Zhang X, Wang J, Shi J, Jia X, Dang S and Wang W. Cost-effectiveness of atezolizumab plus bevacizumab vs sorafenib for patients with unresectable or metastatic hepatocellular carcinoma. JAMA Netw Open 2021; 4: e214846.","DOI":"10.1001\/jamanetworkopen.2021.4846"},{"key":"ref23","unstructured":"Du SY, Weng L and Wu M. Clinical efficacy of TACE combined with camrelizumab in the treatment of patients with intermediate and advanced primary hepatocellular carcinoma. J Pract Hepatol 2023; 26: 116-119."},{"key":"ref24","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1111\/hepr.13592","article-title":"Analysis of efficacy of lenvatinib treatment in highly advanced hepatocellular carcinoma with tumor thrombus in the main trunk of the portal vein or tumor with more than 50% liver occupation: a multicenter analysis","volume":"51","author":"Chuma","year":"2021","unstructured":"Chuma M, Uojima H, Hiraoka A, Kobayashi S, Toyoda H, Tada T, Hidaka H, Iwabuchi S, Numata K, Itobayashi E, Itokawa N, Kariyama K, Ohama H, Hattori N, Hirose S, Shibata H, Tani J, Imai M, Tajiri K, Moriya S, Wada N, Iwasaki S, Fukushima T, Ueno M, Yasuda S, Atsukawa M, Nouso K, Fukunishi S, Watanabe T, Ishikawa T, Nakamura S, Morimoto M, Kagawa T, Sakamoto M, Kumada T and Maeda S. Analysis of efficacy of lenvatinib treatment in highly advanced hepatocellular carcinoma with tumor thrombus in the main trunk of the portal vein or tumor with more than 50% liver occupation: a multicenter analysis. Hepatol Res 2021; 51: 201-215.","journal-title":"Hepatol Res"},{"key":"ref25","unstructured":"Xu W, Wu FL, Chen SB, Zhang Y, Li Y, Wang J, Liu Y, Zhang Y, Zhang Y, Li Y and Zhang H. The effect of oxaliplatin, tegeol chemotherapy combined with ranvartinib in the treatment of elderly patients with advanced liver cancer and its influence on serum tumor markers. Chin J Gerontol 2022; 42: 563-565."},{"key":"ref26","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"RS","year":"2020","unstructured":"Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, Kudo M, Breder V, Merle P, Kaseb AO, Li D, Verret W, Xu DZ, Hernandez S, Liu J, Huang C, Mulla S, Wang Y, Lim HY, Zhu AX and Cheng AL; IMbrave150 Investigators. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med 2020; 382: 1894-1905.","journal-title":"N Engl J Med"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"Rizzo A, Dadduzio V, Ricci AD, Massari F, Di Federico A, Gadaleta-Caldarola G and Brandi G. Lenvatinib plus pembrolizumab: the next frontier for the treatment of hepatocellular carcinoma? Expert Opin Investig Drugs 2022; 31: 371-378.","DOI":"10.1080\/13543784.2021.1948532"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1016\/S1470-2045(21)00252-7","article-title":"Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomiSed, open-label, phase 2-3 study","volume":"22","author":"Ren","year":"2021","unstructured":"Ren Z, Xu J, Bai Y, Xu A, Cang S, Du C, Li Q, Lu Y, Chen Y, Guo Y, Chen Z, Liu B, Jia W, Wu J, Wang J, Shao G, Zhang B, Shan Y, Meng Z, Wu J, Gu S, Yang W, Liu C, Shi X, Gao Z, Yin T, Cui J, Huang M, Xing B, Mao Y, Teng G, Qin Y, Wang J, Xia F, Yin G, Yang Y, Chen M, Wang Y, Zhou H and Fan J; ORIENT-32 study group. Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomiSed, open-label, phase 2-3 study. Lancet Oncol 2021; 22: 977-990.","journal-title":"Lancet Oncol"},{"key":"ref29","doi-asserted-by":"publisher","unstructured":"Llovet JM, Villanueva A, Marrero JA, Schwartz M, Meyer T, Galle PR, Lencioni R, Greten TF, Kudo M, Mandrekar SJ, Zhu AX, Finn RS and Roberts LR; AASLD Panel of Experts on Trial Design in HCC. Trial design and endpoints in hepatocellular carcinoma: AASLD consensus conference. Hepatology 2021; 73 Suppl 1: 158-191.","DOI":"10.1002\/hep.31327"},{"key":"ref30","unstructured":"Zuo YF, Chen XL, Wu SF, Zhang Y, Li Y, Wang J, Liu Y, Zhang Y, Zhang Y, Li Y and Zhang H. Efficacy of camrelizumab-assisted transarterial chemoembolization in the treatment of primary hepatocellular carcinoma and its influence on t lymphocyte subsets and tumor marker levels. J Clin Pharm Ther 2024; 22: 56-60."}],"container-title":["American Journal of Translational Research"],"original-title":[],"link":[{"URL":"https:\/\/e-century.us\/files\/ajtr\/17\/4\/ajtr0160488.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T01:56:23Z","timestamp":1766022983000},"score":1,"resource":{"primary":{"URL":"https:\/\/e-century.us\/files\/ajtr\/17\/4\/ajtr0160488.pdf"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":31,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.62347\/kbmz4400","relation":{},"ISSN":["1943-8141"],"issn-type":[{"value":"1943-8141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025]]}}}